Abstract
Adenylosuccinic acid (ASA) modifies Duchenne muscular dystrophy (DMD) progression in dystrophic mdx mice and human DMD patients. Despite an established role for ASA in augmenting metabolism and cellular energy homeostasis, our previous data suggests an undiscovered ulterior mode of action capable of modifying DMD disease course. Here, we identify ASA as a novel inducer of nuclear factor erythroid 2-related factor-2 (Nrf2), master regulator of the antioxidant and cytoprotective response to cell stress.
Author supplied keywords
Cite
CITATION STYLE
Rybalka, E., Goodman, C. A., Campelj, D. G., Hayes, A., & Timpani, C. A. (2021). Adenylosuccinic acid: a novel inducer of the cytoprotectant Nrf2 with efficacy in Duchenne muscular dystrophy. Current Medical Research and Opinion. Taylor and Francis Ltd. https://doi.org/10.1080/03007995.2020.1865699
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.